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Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common malignancy of the adult kidney and displays heterogeneity in
clinical outcomes. Through comprehensive gene expression profiling, we have identified previously a set of transcripts that
predict survival following nephrectomy independent of tumor stage, grade, and performance status. These transcripts,
designated as the SPC (supervised principal components) gene set, show no apparent biological or genetic features that
provide insight into renal carcinogenesis or tumor progression. We explored the relationship of this gene list to a set of
genes expressed in different anatomical segments of the normal kidney including the cortex (cortex gene set) and the
glomerulus (glomerulus gene set), and a gene set expressed after serum stimulation of quiescent fibroblasts (the core serum
response or CSR gene set). Interestingly, the normal cortex, glomerulus (part of the normal renal cortex), and CSR gene sets
captured more than 1/5 of the genes in the highly prognostic SPC gene set. Based on gene expression patterns alone, the
SPC gene set could be used to sort samples from normal adult kidneys by the anatomical regions from which they were
dissected. Tumors whose gene expression profiles most resembled the normal renal cortex or glomerulus showed better
survival than those that did not, and those with expression features more similar to CSR showed poorer survival. While the
cortex, glomerulus, and CSR signatures predicted survival independent of traditional clinical parameters, they were not
independent of the SPC gene list. Our findings suggest that critical biological features of lethal ccRCC include loss of normal
cortical differentiation and activation of programs associated with wound healing.
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Introduction
In the United States, it is estimated that approximately 54,390
renal cell carcinomas (RCCs) will be diagnosed in 2008, and
13,010 patients will die of their disease [1]. Clear cell renal cell
carcinoma (ccRCC) accounts for approximately 75% of all RCCs,
the most common malignancy of the adult kidney, and the
majority of kidney cancer mortality [2]. Surgery (nephrectomy)
can cure 60%–70% of patients with localized disease and prolong
survival in patients with metastatic disease [3]. While stage, grade
and patient performance status are the most important predictors
of treatment failure they are only modestly successful prognosti-
cators, likely due to underlying molecular heterogeneity that
influences biological behavior [4]. Targeted therapies have
recently emerged that have dramatically altered management of
ccRCC, however, less than half of tumors respond, again likely
reflecting intrinsic differences in the biology of these tumors.
Currently, prognosis after surgery can only be crudely predicted
using traditional clinical outcome measures, and new prognostic
factors and predictive strategies are urgently needed [5].
We and others have used gene expression profiling to identify
gene signatures predictive for outcome in ccRCC. Using a
semisupervised learning algorithm (supervised principal compo-
nents (SPC) analysis), we identified 259 genes represented by 340
transcripts whose expression was associated with survival in a
training set of 88 primary ccRCCs [6]. This gene expression-based
survival predictor, designated the SPC gene set, was a strong
predictor of survival independent of tumor stage, grade, and
performance status in an independent validation set of 89 cases
[6]. One interesting feature of the SPC gene set was that 95% of
the genes show relatively high levels of expression in tumors from
patients with prolonged survival after surgery and low expression
in those with short survival. A similar pattern of expression was
observed by Takahashi et al. in a set of 51 prognostic genes
identified in 29 ccRCCs [7]. Moreover, 15 of these 51 prognostic
genes were found in the SPC gene set, representing a significant
enrichment. However, analysis of the known functions of genes in
the SPC set was unrevealing and showed no enrichment of
biological pathways or functional groups [6]. Therefore, while the
gene sets identified were powerful predictors of outcome, they
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6039yielded few insights into the biological features driving an
aggressive phenotype in ccRCC.
Understanding prognostic signatures discovered by statistical
methods that are agnostic with respect to biology could be
facilitated by comparison to other gene expression signatures
identified with a predefined hypothesis and linked to particular
biological processes. To identify biological threads in the SPC
signature that would provide insight into ccRCC tumor biology,
we compared this gene list to a set of genes expressed in different
anatomical segments of the normal kidney [8] and a gene set
expressed after serum stimulation of quiescent fibroblasts [9]. In
addition, gene signatures of the normal kidney and serum response
signatures were tested for their ability to predict outcome in our
dataset of 177 ccRCC patient samples.
Materials and Methods
ccRCC gene expression and clinical data sets
The ccRCC gene expression data set was generated using fresh-
frozen tissues from 177 patients who underwent radical nephrec-
tomy between 1985 and 2003 in the Department of Urology,
Umea ˚ University Hospital (Umea ˚, Sweden). A detailed description
of the cohort was reported previously [6]. Gene expression
profiling had been carried out on cDNA microarrays containing
over 40,000 clones representing 27,290 unique Unigene clusters.
Fluorescence levels of total RNA compared to Universal Human
Reference RNA (Strategene, La Jolla, California, USA) were
obtained using an Axon GenePix 4000B scanner, with quality
control metrics described previously [6]. Fluorescent ratios were
normalized by mean-centering genes for each microarray, mean
centering each gene across all microarrays and correcting for print
run bias as described previously [6]. Missing data was imputed by
averaging expression values from the 5 nearest neighbors. The
complete microarray dataset is available at http://smd. stanford.
edu/cgi-bin/publication/viewPublication.pl?pub_noJ484. The
data also have been deposited in National Center for Biotechnol-
ogy Information’s Gene Expression Omnibus (Accession Number
GSE3538). We followed the MIAME (Minimum Information
About a Microarray Experiment) guidelines in experimental
design, data analyses and annotation.
Experimentally derived gene expression sets
The SPC gene set includes 259 unique named genes
represented by 340 transcripts that are highly prognostic for
death due to ccRCC independent of clinical and pathological
features. The SPC gene set was identified using supervised
principal components analysis as described previously [6]. The
normal kidney gene expression data set was generated using
dissected renal lobes of five adult human kidneys [8]. The
complete microarray dataset containing 34 samples from the inner
and outer cortex, inner and outer medulla, papillary tips, and
renal pelvis and from glomeruli is available at https://www.med.
stanford.edu/jhiggins/Normal_Kidney/index.shtml. The cortex
gene set encompasses 190 unique named genes represented by 260
transcripts identified by unsupervised hierarchical clustering
analysis [8]. The glomerulus gene set consists of 71 unique named
genes represented by 132 transcripts identified using the same
method as the cortex gene set [8]. All transcripts in the cortex and
glomerulus gene set are expressed at high levels compared to the
other anatomical segments of the normal kidney.
The Core Serum Response (CSR) gene set was derived from
serum stimulation of synchronized fibroblasts from diverse body
sites using the Significance Analysis of Microarrays (SAM)
procedure [10]. Transcripts highly correlated with proliferation
were removed resulting in 400 unique named genes represented by
573 transcripts as described previously [9]. The CSR captures
many transcriptional features normally activated during wound
healing.
Statistical Analysis
Hierarchical clustering analysis. Among all genes that
were well measured (n=14,814) in the ccRCC dataset, we
identified two gene subsets that overlapped with the cortex gene
or the CSR gene lists: the first subset consisted of 87 ‘‘normal
cortex’’ transcripts and the second included 420 CSR transcripts.
We defined well-measured genes as those with a ratio of signal
intensity to background noise of more than 1.5 for either the Cy5-
labeled ccRCC sample or the Cy3-labeled reference sample, in at
least 70% of the samples hybridized. For each gene subset, we
performed average-linkage hierarchical clustering which
segregated the samples into two major groups based on the first
bifurcation of the dendrogram. For the normal cortex gene set, the
survival times of the resulting 2 groups were compared using
Kaplan-Meier survival analysis and the log-rank test using
WinSTAT software. The CSR gene set also segregated tumors
into two groups and these were compared similarly.
Scaling gene expression signatures. The normalized
fluorescence ratios of the 87 normal cortex gene transcripts in
the ccRCC dataset were added to yield to a quantitative score
reflecting the degree of enrichment of the cortex signature for each
sample. Since all of these transcripts were expressed at high levels
in the normal renal cortex, the higher the cortex signature value in
the kidney tumors, the more the sample resembled the normal
renal cortex transcript signature. For each of the 420 CSR related
transcripts in the ccRCC dataset, we assigned +1 to each transcript
if it was expressed at high levels in fibroblasts after serum
stimulation, and 21 if expressed at a low level. The sign corrected,
normalized fluorescence ratios for each of the 420 CSR transcripts
in the ccRCC dataset were summed to provide a score that
reflected the resemblance to the CSR signature for each sample.
Higher scores corresponded to enrichment for expression profiles
observed in serum-activated fibroblasts.
Multivariate proportional-hazards analysis. For both
cortex and CSR signatures, we performed multivariate
proportional-hazards analysis by using either signature as a
continuous variable, together with tumor stage, tumor grade,
and patient performance status. We also performed the
multivariate analysis with group labeling obtained in hierarchical
clustering as a categorical variable. Multivariate proportional-
hazards analysis was performed using the R software package
(available at www.r-project.org).
Results
Normal renal cortex, glomerulus and core serum
response (CSR), overlap significantly with the SPC gene
set
Although the SPC gene set was highly prognostic, analysis of the
known functions of each of the 259 genes in this set did not reveal
common pathways or biological themes that could provide insights
into the biology of lethal ccRCC [6]. To gain insights, we
compared the SPC gene set to another gene expression data set
identified by profiling different anatomical segments of the normal
kidney including the glomeruli, cortex, medulla, papillary tips, and
pelvis. The expression patterns of these genes represent the
transcriptional programs intrinsic to each of these kidney segments
in their normal, fully differentiated state. The cortex signature
consists of 190 named unique genes represented by 260 clones, out
Clear Cell RCC Prognosis
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This overlap (or enrichment) was statistically significant by
permutation test (p,10
24 by 1,000,000 permutations). Specifical-
ly, the number of genes that overlap between the cortex and SPC
genes was significantly greater than that of random gene sets of the
same sizes (190 as cortex genes and 259 as SPC genes) drawn
independently from the total gene pool from which the cortex and
SPC genes were identified. Ten out of 132 transcripts highly
expressed in the glomerulus were found in the SPC gene list,
representing a significant overlap between the two gene lists
although to a lesser degree than the cortex genes (p=0.005 by
1,000,000 permutations). The glomeruli are located exclusively in
the normal renal cortex and genes expressed in isolated glomeruli
reflect additional expression features of differentiated normal renal
cortex. No significant overlap was found between SPC gene set
and gene lists from other anatomic segments of the kidney.
Specifically, 2 of 425 transcripts highly expressed in the renal
pelvis were found in SPC gene list and none of the transcripts
highly expressed in the medulla or papillary tips were found in the
SPC gene list. All individual gene lists and overlapping genes are
provided in Supplemental file S1.
We also compared the SPC gene set with the CSR gene set, a
gene expression program that captures the response of fibroblasts
to serum exposure that is thought to reflect the stereotypical
transcriptional programs activated in fibroblasts during wound
healing [9]. Eighteen out of 353 unique named core serum
response genes were found in the SPC gene set, representing a
significant enrichment (p,10
25 by Chi-square test). All 18 genes
were repressed by serum exposure in fibroblasts, but showed
variation in expression levels across the ccRCC samples. Taken
together, the normal cortex, glomerulus, and CSR gene sets
captured more than 20% of the genes in the highly prognostic
SPC gene set. This suggested the hypothesis that loss of normal
cortical differentiation and gain of features associated with wound
healing are important biological features associated with lethal
ccRCC.
Expression of normal renal cortex and glomerulus genes
predict survival in ccRCC
Out of the 190 named unique genes that are predominantly
expressed in the renal cortex, 67 genes represented by 87
transcripts were well measured and highly variable in the ccRCC
Figure 1. Expression of normal cortex genes predicts survival in ccRCC. (A) Supervised hierarchical clustering analysis of the expression
patterns of 67 cortex genes represented by 87 transcripts in 177 ccRCCs. Each row represents a single gene, and each column a patient sample. The
degree of color saturation corresponds to the ratio of gene expression in each sample compared to the mean expression across all samples. The
distributions of the scaled gene expression scores were shown below the heat map. (B) Kaplan-Meier estimates of disease-specific survival of two
main groups of ccRCC patients defined in (A) based on the cortex gene expression. (C) Kaplan-Meier estimates of overall survival of two main groups
of ccRCC patients defined in (A) based on the cortex gene expression.
doi:10.1371/journal.pone.0006039.g001
Clear Cell RCC Prognosis
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e6039data set (for a complete list of genes and expression levels, see
Supplemental file S2). To test the hypothesis that loss of gene
expression features of the normal renal cortex predicts survival of
ccRCC patients, we first used hierarchical clustering to sort the
177 ccRCC samples based on the 87 ‘‘normal cortex’’ transcripts
found in the ccRCC dataset. As shown in Figure 1A, average
linkage clustering partitioned the samples into two main groups
with predominantly high or low levels of expression of the normal
cortex transcripts (a detailed view of the sample cluster
dendrogram is available in supplemental Figure S1 and the
patient survival information in Supplemental file S3). Kaplan-
Meier survival analysis showed that the patients whose tumors
most resembled normal cortex with high levels of normal cortex
gene expression (cluster 1) had a higher probability of cancer-
specific (Figure 1B, p=0.00007, log-rank test) and overall survival
(Figure 1C, p=0.0003, log-rank test) compared to those with low
expression of cortex genes in their tumors (cluster 2). The median
overall survival for patients in cluster 1 was 39.5 months compared
to patients in cluster 2 which was 22 months. The median disease
specific survival for cluster 1 was 41 months and cluster 2 was 21
months.
In addition, we used alternative methods to validate the
predictive power of cortex genes. First, we calculated the scaled
gene expression score by summing up the log2 based gene
expression ratios of the 87 cortex transcripts well measured in the
177 cRCCs while taking into account the direction of the gene
expression. The distributions of the scores for cluster 1 and cluster
2 were shown in the histogram below the heat map in Figure 1.
Based on the distributions, the sums of the log2 ratios for the
cortex transcripts were overexpressed in the majority of cases in
cluster 1 with good prognosis compared to cluster 2 with poor
prognosis. Second, we divided the samples into two groups at the
median of the sum scaled gene expression and used the group label
for survival analysis. The group with high expression of cortex
genes had a significant better survival than the group with low
expression (p=0.00246, likelihood ratio test), confirming the
predictive power of the cortex gene set.
Like the cortex gene list, the glomerulus genes are all expressed
at high levels in isolated glomeruli from the normal renal cortex,
therefore, high expression of these genes in ccRCC samples
reflects similarity to normal glomerular gene expression patterns.
Fifty out of the 132 transcripts highly expressed in glomerulus were
well measured and highly variable in the ccRCC data set. We
calculated the scaled gene expression by summing up the log2
based gene expression ratios of the 50 glomerulus transcripts while
taking into account the direction of the gene expression. In a
univariate model, high expression for the glomerulus genes
predicted improved survival (p=0.0003). Thus, a gene set that is
enriched for a cell population of the normal cortex also predicted
outcome in ccRCC. Because of the expected overlap in the
patterns of gene expression in the glomerulus gene set with the
normal cortex, we focused our analysis on the cortex gene set.
A Cox proportional hazards model was used to evaluate the
significance of the ‘‘normal cortex’’ gene expression signature in
the context of known clinical prognosticators. Tumors were sorted
into two groups (those whose expression patterns more closely
resembled normal cortex and those that did not) based on the
above hierarchical cluster analysis using the cortex gene set. When
used as a categorical variable, the cortex gene set was a strong
predictor of survival, independent of tumor grade, tumor stage and
patient performance status (Table 1). We also evaluated expression
across the cortex gene set as a continuous variable. For each tumor
sample, we computed a score that represented the sum of the
normalized expression levels for each of the 87 transcripts from the
cortex gene set. Since all transcripts in the cortex gene set are
expressed at high levels in the normal renal cortex, tumors with
high scores had expression patterns that most resembled the
normal renal cortex. When the cortex gene expression score was
used as a continuous variable, it better predicted outcome than the
categorical analysis. Tumors with high cortex gene set scores
showed significantly improved survival, independent of the clinical
prognostic factors (Table 1). Intriguingly, the glomerulus gene set
also predicted outcome as a continuous variable independent of
grade, stage and performance status (p=0.004), although to a
lesser degree than the cortex gene set (p=0.0005).
The SPC genes are highly expressed in the normal renal
cortex
Given the overlap between the cortex and SPC gene sets, we
were curious about the extent to which the SPC gene set captured
normal renal cortical differentiation. We used the SPC gene set to
perform hierarchical clustering analysis of 34 normal kidney
samples that had been dissected from different regions of 5 adult
kidneys [8]. Samples from distinct anatomical regions of the
kidney were segregated with few errors based on their expression
patterns across the SPC gene set (Figure 2). Samples from the
cortex and purified glomeruli were clearly separated from the
samples from the medulla and pelvis. Furthermore, the glomerular
samples formed a distinct group from the cortical samples, while 7
of the 10 the medullary samples clustered separately from the
pelvis and the papillary tips. Samples of pelvis clustered on a
branch together with all the papillary tips. Three of the 5 inner
medulla samples cluster with papillary tips, while the other two
clustered with the outer medulla samples. The majority of the SPC
genes showed high expression in cortex samples. Most notable
included a number of detoxification enzymes such as several UDP
glycosyltransferase 2 family members (UGT2B4, 7, 15, and 17)
and Glutathione S-transferase A2. Therefore, the SPC gene list
captured gene expression features of normal renal differentiation
and best classified the normal cortex samples compared to the
other anatomical segments of the kidney.
Expression of CSR genes predicts survival in ccRCC
The transcriptional signature of the response of fibroblasts to
serum has been shown to be a powerful predictor of the clinical
course in several common carcinomas [9,11]. The enrichment of
CSR genes in SPC gene set suggests that CSR signature may
predict survival in ccRCC and might reflect biological features
captured in the SPC gene list. Out of the 400 unique genes in the
core serum response signature, 353 represented by 420 transcripts
were well measured and highly variable in the ccRCC data set (for
a complete list of genes and expression level, see Supplemental file
S4). Out of the 420 transcripts, 207 were downregulated (down-
sublist) by serum treatment and 213 were upregulated (up-sublist).
Table 1. Multivariate analysis of prognostic values of cortex
gene signature and other clinical parameters.
Variable p-value* Variable p-value*
Cortex-categorical 0.0059 Cortex-continuous 0.0005
Grade 0.4499 Grade 0.302
Performance status 0.0021 Performance status 0.035
Stage ,10
24 Stage ,10
24
*p-values from the analysis of deviance (likelihood ratio test).
doi:10.1371/journal.pone.0006039.t001
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patient samples was performed using this 353 genes, tumors were
partitioned into two main groups (Figure 3A and Supplemental
Figure S1). We calculated the sum of the expression ratios for the
up- and down-sublist for each tumor, and the distributions of the
sum for cluster 1 and cluster 2 were shown in Figure 3A. The
majority of cluster 2 tumors showed high expression of the up-
sublist and low expression of the down-sublist, suggesting an
activation of serum response program. In addition, more cluster 1
tumors than cluster 2 tumors showed low expression of the up-
sublist and high expression of the down-sublist, indicating an
inversed expression of serum response program. Finally, in the
cluster 1 tumors there was a small subset of tumors in which the
up-sublist and many of the down-sublist of genes were expressed at
a higher level, suggesting that the up- and down-sublists were not
coordinately regulated in these tumors. Kaplan-Meier analysis
Figure 2. Hierarchical Clustering Analysis of 34 normal kidney samples using 259 SPC genes. (A) Overview of the gene expression
patterns of SPC genes across the 34 samples. Colored bars identify the locations of the enlargements of the expression map in (C–F). (B) Cluster
dendrogram representing similarities in the expression patterns between experimental samples. Samples were separated into two main groups and
five subgroups (cortex in red, glomeruli in blue, pelvis in orange, medulla in green, and papillary tips in purple). (C) SPC genes specifically
overexpressed in glomeruli. (D) SPC genes specifically overexpressed in cortex and medulla. (E) SPC genes specifically overexpressed in cortex. (F) SPC
genes specifically underexpressed in cortex and glomeruli.
doi:10.1371/journal.pone.0006039.g002
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p=0.001, log-rank test) and overall survival (Figure 3C, p=0.02,
log-rank test) compared to cluster 2. The median overall survival
for cluster 1 was 38 months and for cluster 2 was 25.5 months. The
median disease specific survival for cluster 1 was 38 months and
for cluster 2 was 27 months. These results suggest that activation of
the CSR gene expression program predicts ccRCC survival.
We further examined the predictive power of CSR genes using
an alternative weighted scaling method. Specifically, a CSR index
score was calculated for each sample by summing up the
expression ratios taking into account the direction of regulation
of each gene by serum treatment (see Methods). We sorted the
tumors by their CSR index score and grouped the genes by their
direction of change in response to serum treatment (Figure 4A).
Tumors with high CSR scores were those that displayed gene
expression similar to wound healing (i.e. high expression of genes
upregulated by serum stimulation and low expression of genes
downregulated by serum stimulation). We separated the 177
tumors into two groups using the median CSR index score as the
cutoff. Kaplan-Meier analysis using this grouping criterion showed
tumors with high CSR scores had significant lower cancer-specific
survival than those with low CSR scores (p=0.0007) (Figure 4B).
These results confirmed that activation of the wound-healing gene
expression signature is associated with poor survival in ccRCC
patients.
Multivariate Cox proportional hazards analysis was used to
evaluate the CSR gene list and patient grade, stage, and
performance status in predicting outcome. Tumors grouped by
hierarchical clustering with greater resemblance to the CSR
showed significantly poorer survival compared to those that
showed little CSR expression signature, independent of the clinical
variables. Used as a continuous variable, the weighted CSR score
(based on a sum of the sign-corrected 420 CSR transcripts) better
predicted of cancer specific survival independent of tumor stage
and grade and patient performance status (Table 2).
Robustness of survival prediction by cortex and CSR
genes
We compared random gene lists of the same size as the cortex
and CSR gene lists to test the robustness of survival prediction by
Figure 3. Hierarchical clustering based on core serum response (CSR) gene expression predicts survival in ccRCC. (A) Supervised
hierarchical clustering analysis of the expression patterns of 353 CSR genes represented by 420 transcripts in 177 ccRCCs. The distributions of the
scaled gene expression scores for the up- and down-sublists were shown below the heat map. (B) Kaplan-Meier estimates of disease-specific survival
of two main groups of ccRCC patients defined in (A) based on the CSR gene expression. (C) Kaplan-Meier estimates of overall survival of two main
groups of ccRCC patients defined in (A) based on the CSR gene expression.
doi:10.1371/journal.pone.0006039.g003
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transcript lists with 87 transcripts were constructed and the sum of
expression levels across each gene list was used to predict survival in
a univariate Cox model and the p-value was recorded. None of the
1,000,000 p-values was smaller than that from the cortex gene list,
suggesting a ,10
26 p-value for the significance of cortex gene list.
For the CSR gene list, the same simulation was performed and
the sign information was also randomly distributed on each
simulated gene list. The signed sum was used to predict survival.
Among the 1,000,000 p-values recorded, 3193 records were
smaller than that from the CSR gene list, which suggested a p-
value of 0.0032 for the significance of CSR gene list.
Relationships between the Cortex, CSR, and SPC gene sets
The normal renal cortex and CSR signatures overlapped
significantly in their classification of the 177 ccRCCs into good or
poor prognostic groups. Based on group assignment from the
hierarchical cluster analysis, both the CSR and normal cortex
gene sets categorized 53 cases as having favorable prognosis and
67 as having poor prognosis. As shown in Table 3, approximately
70% of the tumor samples in hierarchical cluster groups with
similar outcomes overlapped (i.e. cluster 1 in Figure 1 and cluster 1
in Figure 3). The similarity in prognostic group assignment was
highly significant (p,10
25 by Chi-square test). Moreover, the
median cortex gene expression score calculated by weighted
scaling method for the favorable group was 32.02 while it was
229.74 for the group with poor survival. On the other hand, the
median CSR score calculated similarly was 273.80 in the
favorable group and 23.48 in those with poor survival. The cortex
score and CSR score were inversely correlated (R=20.5029),
implying that tumors with favorable outcome more closely
resembled the cortex signature and less resembled the core serum
response signature. These results demonstrated that the majority
of the tumors simultaneously showed higher degree of cortical
differentiation and lower level of wounding healing or lower level
of cortical differentiation and higher level of wound healing. In
other words, gene signatures associated with prognosis were
concurrently expressed in the majority of ccRCCs. In multivariate
analysis, the SPC gene set did not predict outcome independent of
the normal cortex gene set. Furthermore, the cortex, glomerulus
and CSR gene sets did not predicted survival independent of the
SPC gene set, implying that SPC gene set captures essential
features of the cortex, glomerulus and CSR gene sets.
Discussion
Clear cell RCC appears to arise from cells in the proximal
convoluted tubules of the renal cortex [13,14]. Inactivation of the
VHL gene and consequent activation of the HIF1 hypoxic
signaling pathway are nearly universal features of ccRCC and
appear to be critical to ccRCC carcinogenesis [15]. More
Figure 4. Weighted scaling expression of CSR genes distinguished ccRCC patients with better survival vs. poor survival. (A) Heat map
of CSR gene expression in 177 ccRCC patients. CSR genes were separated into up- and down-sublists based on their response to serum. ccRCC
samples were sorted by the sum of CSR gene expression ratios in each tumor calculated while taking into account their direction of changes in
response to serum. (B) Kaplan-Meier estimates of disease-specific survival of two groups of ccRCC patients defined using the median of the weighted
scaling expression of CSR genes as a cutoff.
doi:10.1371/journal.pone.0006039.g004
Table 2. Multivariate analysis of prognostic values of CSR
gene signature and other clinical parameters.
Variable p-value* Variable p-value*
CSR-categorical 0.0206 CSR-continuous 0.0473
Grade 0.475 Grade 0.2062
Performance status 0.0030 Performance status 0.0037
Stage ,10
24 Stage ,10
24
*p-values from the analysis of deviance (likelihood ratio test).
doi:10.1371/journal.pone.0006039.t002
Clear Cell RCC Prognosis
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disease and underlie lethality. Perhaps the most striking feature of
prognostic gene sets arising from profiling studies of Takahashi
and colleagues and our group is that nearly all transcripts
correlated with survival show lower levels of expression in the
most aggressive tumors. We observed highly significant overlap
between our prognostic (SPC) gene list and a set of genes highly
expressed in the normal renal cortex and normal glomeruli. Loss
of expression of the normal cortex and glomeruli genes in the
ccRCCs was associated with decreased survival, and the
prognostic value of the normal cortex genes was similar to (and
not independent of) the SPC gene list. The SPC prognostic gene
list was able to correctly sort samples from anatomical segments of
the normal kidney and was particularly good at grouping samples
from the normal cortex and glomeruli. Therefore, one of the most
important biological features of the SPC gene set is that it captures
the transcriptional program of the terminally differentiated normal
renal cortex. Loss of the transcriptional program associated with
renal cortical differentiation is an important feature of aggressive
ccRCC and highly predictive of cancer-specific death.
The SPC gene set also appears to embody features of the core
serum response. Again, there was significant enrichment for the
CSR genes in the SPC prognostic gene set. The CSR set also was
highly predictive of survival in ccRCC, independent of known
clinical prognostic parameters. Intriguingly, tumors with expres-
sion features that more closely resemble the CSR gene set show
less similarity to the expression patterns of the normal renal cortex.
In other words, loss of transcriptional patterns associated with
normal cortical differentiation was associated with acquisition of
those of the core serum response. The CSR signature does not
reflect proliferation since all of the proliferation-related genes have
been removed by cross-referencing to a comprehensive list of cell-
cycle regulated genes identified by Whitfield et al. [16]. The core
serum response does display many aspects of wound healing and
previous work has suggested that the cancer microenvironment
resembles a wound that does not heal [17]. Similarities in gene
expression profiles of ccRCC and renal regeneration and repair
have been reported previously, although this relationship was not
tested for effects on clinical outcome or survival [18]. The CSR
has been found to provide independent survival prediction in
several of caner types [9,11] and our study is the first to show that
it predicts survival in ccRCC.
The absence of the CSR signature in the ccRCCs with favorable
outcomes might reflect a tumor microenvironment that does not
promote tumor progression. Alternatively, since fibroblasts invoke
features of mesenchyme during wound healing including activation
and migration, it is conceivable that acquisition of ‘‘wound healing’’
is associated with EMT. In addition, loss of differentiation and gain
of EMT during tumor progression has been observed in a number
of tumor types [19]. For example, gastric cancer cells with
fibroblastoid morphological changes show increased motility and
invasiveness due to decreased cell-cell adhesion, reminiscent of
EMTduring embryonic development[19].EMThas beenreported
to be an integral component of colorectal and breast cancer
progression [21,22]. In our dataset, concomitant loss of differenti-
ation and acquisition of ‘‘wound healing’’ was associated with
features of EMT including down regulation of the epithelial marker
CDH1 and up regulation of the mesenchymal markers FN1 and
VIM (for detailed information see Supplemental file S5 and S6),
suggesting that EMT may play a role in clear cell renal cell
carcinoma progression.
The use of normal tissue gene expression signatures for
prognostication has been reported in diffuse large cell B
lymphomas (DLBCL) [23]. Alizadeh and co-workers identified
two molecularly distinct forms of DLBCL that have gene
expression patterns resembling different stages of B-cell differen-
tiation. DLBCLs that express genes characteristic of normal
germinal center B cells have significantly better overall survival
than those with expression features resembling circulating blood B
cells that have been activated in vitro. Taken together with our
data, these findings suggest that better understanding of normal
tissues and the programs that regulate their development could
provide insights into cancer progression. Furthermore, our
findings suggest that expression patterns from normal tissues have
potential as prognostic signatures for the malignancies that arise
from them. Similarities in gene expression patterns between
tumors with favorable prognosis and normal tissues also
strengthens the rationale of promoting normal differentiation in
malignant cells as an alternative to cytotoxic therapy or as a
secondary prevention strategy.
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Table 3. Comparison of the groupings using the cortex and
the CSR genes.*
Cluster 1
(Figure 3)
Cluster 2
(Figure 3)
Total
cases Outcome
Cluster 1 (Figure 1) 53 31 84 good
Cluster 2 (Figure 1) 26 67 93 bad
Total cases 79 98
Outcome good bad
*The overlapping is statistically significant by Chi-square test (p,10
25).
doi:10.1371/journal.pone.0006039.t003
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